目的 观察玛巴洛沙韦治疗儿童流行性感冒的有效性与安全性。方法 回顾性选取2024年1月—2025年2月徐州医科大学附属医院接受治疗的115例流行性感冒患儿，根据不同治疗方案分为对照组（n=60）与观察组（n=55）。对照组给予磷酸奥司他韦颗粒治疗，观察组给予玛巴洛沙韦片治疗。比较两组的治疗效果、临床症状缓解时间、炎症因子[超敏C反应蛋白（hs-CRP）、血清淀粉样蛋白A(SAA)、白细胞介素6(IL-6)]、肝功能指标[丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）]、肾功能[尿素氮（BUN）、肌酐（Scr）]及不良反应。结果 观察组总有效率优于对照组（P<0.05）；观察组完全退热、咳嗽咳痰缓解、咽痛消失时间均短于对照组（P<0.01）；与同组治疗前比较，治疗后两组SAA和IL-6水平均显著降低（P<0.01）；且观察组SAA、IL-6水平均低于对照组（P<0.01）；治疗前后两组hs-CRP、ALT、AST、BUN、Scr比较差异无统计学意义（P>0.05）。两组不良反应比较差异无统计学意义（P>0.05）。结论 玛巴洛沙韦对流行性感冒患儿有良好疗效，可有效改善临床症状及抑制炎症反应，加快患儿康复，临床应用安全性好。

Objective To evaluate the clinical effectiveness and adverse reaction profile of baloxavir marboxil as a therapeutic intervention for pediatric influenza cases. Methods A retrospective selection was made of 115 children with influenza who were treated in the Affiliated Hospital of Xuzhou Medical University from January 2024 to February 2025. They were divided into the control group（n = 60） and the observation group（n = 55） according to different treatment regimens. The standard treatment group received oseltamivir phosphate in granule form, whereas the experimental cohort was administered oral Baloxavir Marboxil Tablets. Compare the therapeutic effects, clinical symptom relief time and inflammatory factors [hypersensitive C-reactive protein（hs-CRP）, serum amyloid A（SAA）, interleukin-6（IL-6）], liver function indicators [alanine aminotransferase（ALT）, aspartate aminotransferase enzyme transferase（AST）], renal function [blood urea nitrogen（BUN）, serum creatinine（Scr）] and adverse reactions of the two groups. Results The total effective rate of the observation group was superior to that of the control group（P ＜0.05）. The observation group showed shorter times for complete fever resolution, cough and expectoration relief, and throat pain disappearance compared to the control group（P ＜0.01）. Compared with the same group before treatment, the average levels of SAA and IL-6 in both groups were significantly lower after treatment（P ＜0.01）. Serum SAA and IL-6 levels in the observation group were lower than those in the control group（P ＜0.01）. Compared with before treatment within the same group, the levels of SAA and IL-6 in both groups were significantly lower after treatment（P ＜0.01）; The levels of SAA and IL-6 in the observation group were lower than those in the control group（P ＜0.01）; No significant differences were found in hs-CRP, ALT, AST, BUN, or Scr between the two groups（P ＞ 0.05）. There was no significant difference in adverse reactions between the groups（P ＞ 0.05）. Conclusion Baloxavir marboxil has a good therapeutic effect on children with influenza. It can effectively improve clinical symptoms and inhibit inflammatory responses, accelerate the recovery of children, and has good clinical application safety.

R978.7